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Kahlbaum first described catatonia; later Kraepelin, Gjessing, and Leonhard each defined periodic catatonia differently. A 48-year-
old female with catatonia, whose grandmother probably died from it, was prospectively followed for >4 years in a US psychiatric
state hospital. Through 4 catatonic episodes (one lasting 17 months) there were menstrual exacerbations of catatonia and increases
in 4 biological variables: (1) creatine kinase (CK) up to 4,920 U/L, (2) lactate dehydrogenase (LDH) up to 424 U/L, (3) late
afternoon cortisol levels up to 28.0 mcg/dL, and (4) white blood cell (WBC) counts up to 24,200/mm3 with neutrophilia without
infections. Records from 17 prior admissions documented elevations of WBC and LDH and included an abnormal dexamethasone
suppression test (DST) which normalized with electroconvulsive therapy. Two later admissions showed CK and WBC elevations.
We propose that these abnormalities reflect different aspects of catatonic biology: (1) the serum CK, the severity of muscle damage
probably exacerbated by the menses; (2) the hypercortisolemia, the associated fear; (3) the leukocytosis with neutrophilia, the
hypercortisolemia; and (4) the LDH elevations, which appear to be influenced by other biological abnormalities. Twentieth-century
literature was reviewed for (1) menstrual exacerbations of catatonia, (2) biological abnormalities related to periodic catatonia, and
(3) familial periodic catatonia.
1. Introduction
Catatonia is one of the six types of psychiatric disease
described by Kahlbaum [1]. After the publication of his
catatonia monography in 1874 [2], Seglas and Chaslin [3]
proposed that catatonia was better categorized as a syndrome,
while Kraepelin thought that catatonia should be included
as part of the diagnosis of dementia praecox (later renamed
schizophrenia) [4]. Under Kraepelin’s influence, the DSM-3
considered catatonia to be a type of schizophrenia [5] but the
progressive influence of Fink and Taylor [6] led to changes in
the subsequent editions, until DSM-5 [7] classified catatonia
as a syndrome that occurs (1) in association with another
mental disorder (catatonia specifier), (2) due to another
medical condition, or (3) as unspecified catatonia.The DSM-
5’s unspecified catatonia probably reflects two overlapping
concepts: idiopathic recurrent catatonia from psychiatry in
the English-speaking world [8] and periodic catatonia from
continental European psychiatry.
1.1. Periodic Catatonia. Kraepelin and two other lesser known
Europeans, Gjessing and Leonhard, are associated with the
concept of periodic catatonia. Kraepelin [4] described cata-
tonic stupor and catatonic excitement (including periodic
catatonic excitement), but considered catatonia to be part
of schizophrenia. Gjessing [9–22], a Norwegian psychia-
trist, fully developed the concept of periodic catatonia and
focused his research career on the biological abnormalities
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of patients with periodic catatonia. Before the introduction
of psychotropic drugs, he estimated that periodic catatonia
accounted for 2-3% of schizophrenia but that psychotropic
drugs changed the periodicity of the symptoms [10]. Leon-
hard, a German, was the last member of theWernicke-Kleist-
Leonhard school [23]which developed an alternative toKrae-
pelin’s classification of psychoses. Leonhard [24] conceptual-
ized periodic catatonia as a type of unsystematic schizophre-
nia (i.e., genetically based schizophrenia) in contrast to sys-
tematic (nonperiodic and nonfamilial) types of schizophre-
nia. Later, German researchers following Leonhard proposed
that periodic catatonia is a familial disorder and suggested
some possible gene candidates; he considered it different
from typical presentations of schizophrenia [25–27].
1.2. Biological Abnormalities in Periodic Catatonia. Rolv
Gjessing [9] made many biological observations of patients
with periodic catatonia, but he focused on abnormalities
in nitrogen metabolism. Summarizing his life’s work, his
son, Leiv Gjessing, explained that these biological abnor-
malities did not occur simultaneously with the stuporous or
excited phases; rather, they were abnormalities that could
be corrected with thyroid supplementation [10]. According
to Gjessing, the following biological abnormalities can be
seen [9, 10]: (1) glucose abnormalities (excitement phase
characterized by elevated fasting blood glucose and stuporous
phase marked by elevated blood glucose in the glucose tol-
erance test) and (2) leukocytosis with neutrophil granulocy-
tosis (“moderate” leukocytosis during the excited phase and
“marked” leukocytosis during the stuporous phase). More
recently, Lee et al. [28, 29] described mild leukocytosis in 3 of
20 patients with catatonia not complicated by medical issues.
After reviewing 13 articles [9–21] and a book [22] in
English written by R. and L. Gjessing (father and son)
regarding R. Gjessing’s work, it is clear that their collection
of longitudinal biological data is impressive although the
clinical descriptions and conclusions are often opaque. The
clinical description of familial periodic catatonia by Leonard
and his disciples [24] is more cohesive and understandable in
a contemporary context.
Table 1 describes adrenal abnormalities in 8 published
patients with periodic catatonia [30–36]. Of the 8 cases
(5 males and 3 females): (1) three showed no relationship
between urinary steroids and catatonia [30, 32, 33], (2) one
showed a decrease in urinary steroids during the excitement
phase [31], (3) one showed a decrease in urinary steroids
during the stuporous phase [33], (4) two cases showed an
increase in urinary steroids during the stuporous phase [31,
33], and (5) one case described byMcCall [34] responded to a
dexamethasone suppression test (DST) with nonsuppression
during stupor which normalized with recovery.
1.3. Catatonia and the Menses. Kraepelin [4] was the first
to notice that periodic attacks of excitement in dementia
praecox were sometimes related to the menses in women.
Brockington, an expert in the effects of menses and psychosis
[37], has published an encyclopedic review [38] of menstrual
psychosis including 80 patients who were previously pub-
lished by or reported to him. He highlighted 3 patients with
catatonic symptoms; none of them had stuporous episodes
[36, 39, 40], but 2 of them appeared to have menstrual
exacerbations of epilepsy [39, 40]. Kobayashi and Kato
[41] described an 18-year-old woman diagnosed with cata-
tonic schizophrenia who had repeated catatonic stuporous
episodes of premenstrual onset (7 days before). As far as
we can tell, the literature describes no cases of patients with
periodic catatonia in whom the onset of menses was asso-
ciated with the onset of catatonia. Leonhard [24] described
menstrual exacerbations in some patients with catatonic
symptoms diagnosed with cycloid psychoses, but did not
describe menstrual exacerbation in periodic catatonia.
1.4. Catatonia and Low Serum Iron. In 1991, Rosebush and
Mazurek [42] first suggested that low serum iron can be a
potential biological marker and possibly a contributing factor
for the development of neuroleptic malignant syndrome
(NMS). Later, in 1998, Lee [43] proposed that low serum iron
in malignant catatonia may be a risk factor for NMS. Some
authors have found that relatively low serum iron within
the normal range may be associated with acute catatonia
[44, 45]. Lee [28, 43] proposed that low serum iron in
excited catatonia may be associated with an unfavorable
benzodiazepine response.
2. Case Presentation
The supplemental material presents in Section S1 details con-
cerning the assessments; 3 subsections describe: S1.1 rating
scales [46–49], S1.2 laboratory studies [50–53], and S1.3 men-
struation. Section S.2 is on statistics [54–59].The rating scales
include the Bush-Francis Catatonia Rating Scale (BFCRS)
and the Abnormal Involuntary Movement Scale (AIMS).
Supplementary Table S1 provides the limited laboratory
studies from prior private psychiatric hospital admissions.
Supplementary Table S2 describes the routine laboratory
studies conducted at the state psychiatric hospital including
creatine kinase (CK), lactate dehydrogenase (LDH), after-
noon (3 PM) cortisol, white blood cell (WBC) count, and
absolute neutrophil count (ANC). Table 2 provides a very
brief summary of Supplementary Table S2. Supplementary
Table S3 summarizes the descriptive analyses of the biological
variables measured during the second catatonic episode.
2.1. Prior History
2.1.1. Description of the Patient. On her first admission to
our state psychiatric hospital, the patient was a 48-year-old
single white female. The patient signed a consent form for
a pharmacogenetic research study approved by two institu-
tional review boards in which she provided permission for
publication of her data and clinical information. Beginning
at age 34, she had had 17 admissions to private psychiatric
hospitals (Supplementary Table S1) during the 1980s and
1990s.During the late 1990s and early 2000s, shewas admitted
to the state psychiatric hospital over the course of more than
4 years (1567 days) (Supplementary Table S2). The patient
was born prematurely and her mother experienced a difficult
labor. She also had Rh factor incompatibility and required a
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Table 1: Adrenal abnormalities in 8 published patients with periodic catatonia1.
First author
Year Country Case
Age
& sex
Retrospective
diagnosis2 Endocrine measure
Ashby [30]
1952 England 38C Schizophrenia
Patient improved with ECT but urinary
17-ketosteroids unchanged
Gornall [31]
1953
Canada
2 36D Schizophrenia ↓ urinary 17-ketosteroids during excited phase,normal in interval
3 33C Schizophrenia ↑ urinary steroids during stupor phase, normalin interval
Cookson [32]
1966 Canada 22C Schizophrenia
No relationship between ↑urinary
17-ketosteroids and stupor
Vesterggard
[33]
1969
USA
1 47D Schizophrenia ↓ urinary steroids during stupor
2 40D Schizophrenia ↑ urinary steroids during stupor
3 29D Schizophrenia No relationship between urinary steroids andstupor
McCall [34]
1989 USA 60D
Idiopathic
recurrent
catatonia3
Lack of DST suppression during stupor,
normalized with recovery
1Eight patients were excluded as they did not have clearly distinct episodes of periodic catatonia, including two patients described by Gunne and Gemzell [35]
and six patients (Cases 1, 2, 3, 4, 9, and 10) described by Hatotani et al. [36]. Case 1 by Gornall et al. [31] and Cases 5, 6, 7, and 8 by Hatotani et al. [36] are not
included among the 16 patients with measures of adrenal function, due to lack of these measures.
2Retrospective DSM-5 diagnoses by agreement between two of the authors.
3There is no family history of catatonia but the patient’s symptoms appeared similar to our patient. As a matter of fact, the patient had some “preoccupation
with guilt and punishment” as did our patient.
blood transfusion after significant hemolysis. The outcome
of these delivery complications was left-sided cerebral palsy.
Although her mother died three days after childbirth, the
patient experienced a stable childhood, completed college,
andwent on to become a teacher. At timeswhen she did expe-
rience difficulties in her job, her aunt, the school supervisor,
was available to help. She never used tobacco products, alco-
hol, or drugs. She had undergone several magnetic resonance
imaging (MRI) studies prior to presentation, which failed to
show any acute abnormalities and were remarkable only for
nonspecific periventricular white matter changes.
2.1.2. Prior Psychiatric Admissions. The patient’s first psychi-
atric hospitalization occurred at age 34 for psychosis. Accord-
ing to the discharge summary from this first admission, the
patient had been treated intermittently with benzodiazepines
for two years by her family doctor. The discharge summaries
from most of these 17 prior hospitalizations were obtained
and summarized in Supplementary Table S1.
2.1.3. Family History. The patient’s paternal grandmother
had died at age 37 at a psychiatric hospital, and the death
certificate listed cause of death as exhaustion from toxic
psychosis. She had been hospitalized for seven days prior to
death. According to some of the most experienced academic
psychiatrists familiar with diagnosis in the early 20th century
in Kentucky, it is likely that this death certificate meant
that the grandmother died of severe agitation during a
catatonic episode before psychiatric medications or ECT
were available. The patient’s father never had any catatonic
symptoms, according to family members, nor did her mother
who died young three days after childbirth. Her only siblings
were half-siblings.
2.2. Admission to the State Psychiatric Hospital. The periods
between the catatonic episodes have been moved to Supple-
mentary Section S3 and the outcome after the admission to
the state psychiatric hospital to Supplementary Section S4.
2.2.1. Before First Catatonic Episode Was Diagnosed by the
Senior Author. The patient’s mental health began to decline
two months prior to admission; she became increasingly
delusional and struggled to care for herself. The patient was
brought to the hospital by family members after an episode of
yelling and pounding on the walls and striking out at nurses
at the patient’s personal care home, to which she had been
discharged from a private psychiatric hospital that same day.
The family attempted to return the patient to that hospital
but they were referred to the state hospital for long-term
care. Her behavior was difficult to control, she attempted to
climb out of a moving vehicle, and she was very delusional
and religiously preoccupied. Shewas prescribed the following
medications prior to the presentation to the state psychiatric
hospital: diazepam up to 20mg/day as needed, clomipramine
50mg/day, haloperidol 20mg/day, benztropine 4mg/day, and
divalproex sodium 750 mg/day.
The day of admission to the state psychiatric hospital
in the late 1990s will be considered day 1. On that day she
was described as severely agitated, screaming, combative,
and aggressive, which is compatible with an excited catatonic
state, but the admitting psychiatrists did not use the word
catatonia. For the first several days of admission she was
admitted to the acute care unit and treated with the same
medications prescribed by themost recent private psychiatric
hospital. During this time, her agitation was often treated
with 2-mgdoses of oral or intramuscular (IM) lorazepam. She
was then transferred to an intermediate care unit from day
4 Case Reports in Psychiatry
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6 to day 136. All psychiatric medications except lorazepam
were initially discontinued. The patient began to make
improvements and olanzapine 20mg/day was added. She had
a sudden worsening of agitation on day 120 for no apparent
reason, but the chart had no information on the menses.This
episode of agitation was treated primarily with lorazepam as
needed. On day 132, the treating psychiatrist reported that the
episodes of agitation responded well to lorazepam and so he
decided to add clonazepam 1 mg/day to the treatment.
2.2.2. First Catatonic Episode Diagnosed and Assessed with
the Bush-Francis Scale (10 Days). On day 137, the patient
was transferred to the long-term unit managed by the senior
author. She exhibited no clear catatonic signs and was being
treated with 1 mg/day of clonazepam and 20 mg/day of
olanzapine.
On day 194, the patient started her menses. She appeared
to have “overwhelming anxiety” and reported “anxiety in her
body”. She was treated with 2 mg of oral lorazepam. She
also had problemswith eye contact, answering questions, and
non-goal-directed hyperactivity, but the senior author did not
realize these were initial catatonic symptoms. On day 196,
the senior author realized that the patient definitively had
catatonic signs (Supplementary Table S2). This first catatonic
episode lasted ten days and was treated with lorazepam up
to 6 mg/day added to her prior treatment of 1 mg/day of
clonazepam and 20 mg/day of olanzapine.
2.2.3. Second Catatonic Episode (17 Months). During her
convalescent leave, on day 338, the patient stopped taking
lorazepam and began hermenses the next daywhen catatonia
reemerged. She entered a prolonged period of 17 months
during which time she was treated with lorazepam and even-
tually ECT after much hesitation from the patient. Menses
frequently exacerbated her symptoms. Supplementary Table
S2 describes her symptoms and laboratory values. Testing for
porphyria and syphilis was negative.
2.2.4. Third Catatonic Episode (14 Days). On day 1271 she
started her menses and the next day she went to the academic
general hospital for ECT but did not receive it due to a
misunderstanding. On day 1276, she again presented for
ECT (5 weeks after the prior ECT) but after the treatment
she became extremely agitated and had to be moved to the
emergency room (ER) of the academic hospital, where the
senior author was called in to manage her. She was treated
with lorazepam 8mg IV and then sent to the state psychiatric
hospital. Over the next 10 days she received 3 ECT treatments
plus the 6 mg/day of oral lorazepam. On day 1286, the patient
returned to baseline and was placed on convalescent leave.
2.2.5. Fourth Catatonic Episode (4 Days). The patient expe-
rienced one final brief episode of catatonia. On day 1563,
the psychiatrist who provided ECT reported that the patient
had been vomiting for 3 days and was unable to take her
lorazepam, resulting in combative behavior thatwasmanaged
by the family. There were no labs drawn because the patient
was on convalescent leave and the catatonic episode resolved
after the ECT was moved forward to day 1564 and another
ECT on day 1567 was added. After those two ECTs she
returned to baseline. After this last catatonic episode, the ECT
was scheduled every 3 weeks and then moved to every 2.5
weeks to avoid paranoid ideation between ECT sessions. On
day 1599, the patient was discharged on lorazepam 6 mg/day
and ECT every 2.5 weeks and never readmitted.
3. Biological Abnormalities
The data on the less important biological abnormalities has
been moved to Supplementary Section S5 which includes
two subsections on platelets (S.5.1.) and iron supplementation
(S.5.2.).
3.1. Exacerbations of Catatonia with Onset of Menses
3.1.1. Clinical Data from the State Psychiatric Hospital. Once
the relationship between the menses and the first catatonic
episode was established, the family indicated, after question-
ing, that the patient had suffered multiple previous catatonic
episodes associated with the onset of her menses. As a matter
of fact, within 30 days before admission to the state psychi-
atric hospital (Supplementary Table S1), the patient was taken
to a private psychiatric hospital for her 17th admission after
the family found her at home standing in the shower for sev-
eral hours, completely mute and immobile. According to the
family that catatonic episode started on day 1 of the menses.
The first episode of the patient’s catatonia that was
observed by the senior author occurred when the patient
was 49 years old and starting the first day of her menstrual
cycle. It appears that the treatment at that time (20 mg/day
of olanzapine and 1 mg/day of clonazepam) was not enough
to prevent a catatonic relapse. Catatonia resolved by day 11 of
this menstrual cycle after treatment with lorazepam. She was
placed on convalescent leave and had no relapses for three
menstrual cycles.
The second catatonic episode, in which catatonia ree-
merged and become refractory to high doses of benzodi-
azepines, started after the patient stopped taking lorazepam
and began her menses the next day.The episode persisted for
17months, including three regularmenstrual cycles and times
of irregular menses. Her menstrual cycles were sometimes
three weeks apart, and other timesmore than sixty days apart.
At other times the patient had light flow or menses for only
two days at a time. Due to the association of the onset of
catatonia with the menses, oral medroxyprogesterone was
started in an attempt to regulate the female sexual hormone
fluctuations associated with the menses.This medication was
increased to 12 mg/day over the course of three months in
the context of low serum progesterone levels. The patient
did not show any improvement and medroxyprogesterone
was stopped.The catatonic episode resolved when the patient
finally agreed to proceed with ECT treatment, which ap-
peared to help recover her response to benzodiazepines [60].
During the 12 months of convalescent leave between the
second and third catatonic episodes, the menses were not
associated with catatonic symptoms while the patient was
on maintenance treatment with both lorazepam and ECT.
The patient had a sudden lorazepam withdrawal episode due
6 Case Reports in Psychiatry
to lack of a prescription which manifested as a withdrawal
seizure rather than catatonia, but this event did not coincide
with the menses.
The third catatonic episode resulted from the combina-
tion of menses onset and a missed ECT treatment the next
day due to a hospital misunderstanding. She recovered in 14
days after very aggressive treatment.
During the nine months of convalescent leave between
the third and fourth catatonic episodes, the menses did
not exacerbate any catatonic symptoms while she was on
maintenance treatment with lorazepam and ECT. The last
menstrual period started on day 1479 and after that she did
not have any more menstrual periods. After 2.5 months of
being menopausal she had a short final catatonic episode
after 3 days of vomiting and probably not absorbing the oral
lorazepam, which resolved with ECT.
In summary, the menses led to (1) the first catatonic
episode when the patient was taking a low dose of benzo-
diazepines, (2) the second catatonic episode only after the
patient also stopped taking lorazepam, and (3) the third
catatonic episode only after the patient also was delayed in
receiving ECT.
3.1.2. Statistical Association between Menses and Biological
Variables during the Second Catatonic Episode. The visual
inspection of means and percentage of abnormal values
(lower panel of Supplementary Table S3) indicated thatWBC,
granulocytes, and LDH did not appear to be associated with
the menses. On the other hand, CK elevations appeared to
have the potential to be associatedwith themenses since there
were 7 days with menses which had a median CK of 477 U/L
and 39 days without menses which had a median of 71 U/L
(Supplementary Table S3, footnote 6).
Using the SPSS autocorrelation module, we verified that
the assumption of independent observations was not violated
and statistical tests can be used to explore significant differ-
ences in this variable (Supplementary Table S3, footnote 6).
Therefore, the independent sample Mann–Whitney U test
provided a p=0.002, indicating that menses was significantly
associated with CK elevations.
3.2. CK and LDH Elevations
3.2.1. Data from the State Psychiatric Hospital. During the
ten days of the first catatonic episode at the state psychiatric
hospital, CK values ranged from 1957 U/L on the third day
of that episode (day 196) to 159 U/L on the tenth day of the
episode (day 203). On the tenth day, the CK value was not
yet normal despite the fact that the catatonic symptoms were
no longer present. Due to the abnormal laboratory findings
during this time, particularly the CK elevation of 1957 U/L,
the patient was sent to the academic general hospital for
further testing. She was returned to the state psychiatric
hospital on day 197, with the comment thatmyocardial infarct
had been ruled out.
The second catatonic episode lasted 17 months and was
characterized by an irregular oscillating pattern of CK values.
The highest value was 4920 U/L on day 372, 32 days after
the onset of this second episode. From day 483 to day 721,
the patient had catatonic symptoms but the CK value was
within normal limits. There were no CK values during the
first days of the third catatonic episode but the CK value
was normal on the eleventh day of this episode (day 1282).
There were no CK values taken during the fourth catatonic
episode because she was not admitted to the state psychiatric
hospital.
There were no LDH elevations during the first and third
catatonic episodes, which were relatively short-lived.The first
catatonic episode lasted only 10 days and LDH was always
normal despite the peak CK elevation of almost 2000 U/L.
The third catatonic episode lasted only 14 days; both the
two LDH values and the CK value were normal. No CK or
LDHvalues were studied during the fourth catatonic episode.
During the 17months of the second episode, two occurrences
of LDH elevation were detected.The first occurrence of LDH
elevation lasted 20 days and started on day 371, 30 days after
the first CK elevated value, and at the same time CK peaked
(>1,000 U/L on day 371 and almost 5,000 U/L on day 372).
The second occurrence lasted only during day 411, which was
the same day that CK again was > 1,000 U/L.
3.2.2. Statistical Association between LDH and Other Biologi-
cal Variables during the Second Catatonic Episode. Amultiple
linear regression model with LDH as the dependent variable
and 3 independent variables, CK,WBC, and cortisol, showed
good adjustment (adjusted R square =.687). The 3 variables
were significant after adjusting by the others: CK (p<0.001),
WBC (p=0.002), and cortisol (p=0.027). The standardized
residuals showed no significant autocorrelation and partial
correlations did not reach the upper and lower limits of the
confidence intervals.
3.2.3. Data from the Prior Psychiatric Admissions. After the
arrival of the documents from most of the 17 admissions to
private psychiatric hospitals, it was clear that serum CK was
never measured; however, LDH elevations were described
in the seventh and tenth of these 17 admissions (Supple-
mentary Table S1). The only explanation for the elevated
LDH occurred when the level reached 733 (second private
hospital, tenth admission), when the physicians attributed
this abnormal laboratory finding to “bruising”. The possi-
bility of catatonia was not considered although the patient
was described as very agitated and she was diagnosed with
mania. In our experience at the state psychiatric hospital,
the patient only developed bruises when she was severely
agitated during catatonic episodes (self-induced bruises were
definitively noted during the second and third episodes).
Therefore, we suspect that the LDH elevation of the tenth
admission in the private psychiatric hospitals was due to a
severe catatonic episode with extreme agitation, comparable
to the LDH elevations seen at the state psychiatric hospital
during the second catatonic episode.
3.2.4. Data from the Later Psychiatric Admissions. On day
3749 the patient was admitted to the community hospital
with catatonic signs. A CK elevation reaching 1800 U/L led
to consideration of NMS and a transfer to the university
hospital. The intervention of the psychiatry department led
Case Reports in Psychiatry 7
to recovery and normalization of CK through the use of ECT
and lorazepam (Supplementary Table S1).
3.3. Hypercortisolemia
3.3.1. Data from the State Psychiatric Hospital. During the
first episode of catatonia, cortisol was not directly mea-
sured. Drawn labs included hemogram, and metabolic and
cholesterol panels which showed an elevated WBC of 12.3
x 103/mm3, elevated glucose of 131 mcg/dL, and elevated
cholesterol of 227 mcg/dL. After the first catatonic episode
resolved, the senior author suspected that the presence of
hyperglycemia and leukocytosis without infection indicated
an episode of hypercortisolemia.Therefore, when the second
episode of catatonia started, cortisol wasmeasured on the first
day of the episode, day 341, providing an extremely high level
of 28 mcg/dL (Supplementary Table S2).
During the second catatonic episode, labs were drawn
more often than during the first episode due to the confirmed
suspicion for hypercortisolemia. Elevations in cortisol were
found on nine separate days that labs were checked. During
this second catatonic episode, 48% (23/48) of ANC and 64%
(33/52) ofWBCwere above the normal limits.Therewere two
periods in which the ANC increased to >16 x 103/mm 3 and
the WBC increased to >20 x 103/mm.3 Both occurred when
the cortisol values were also extremely high: >20 mcg/dL.
During the third episode of catatonia, WBC and cor-
tisol were not measured on the first day of the catatonic
episode, but the patient had a dramatic WBC elevation of
24.2 x 103/mm3 on day 1276 which was the third day of
catatonic symptoms (Supplementary Table S2); cortisol was
not checked on that day. Cortisol was later measured only
once, on day 1282, and was within the normal range. No labs
were checked during the fourth episode of catatonia.
3.3.2. Data from the Prior Psychiatric Admissions. Therecords
from the private psychiatric hospitals indicated thatDSTs had
been completed twice (Supplementary Table S1). At the time
(late 1980s), many psychiatric hospitals used DST as part of
the workup for depression [61].
During the patient’s first psychiatric admission, the DST
test was performed before and after her ECT treatments. Prior
to ECT, herDST revealed nonsuppression of cortisol with val-
ues of 8.7 and 9.8 mcg/dL. After ECT, her DST revealed nor-
mal suppression of cortisol with values of 0.9 and 0.8mcg/dL.
Additionally, during this admission, her WBC was found to
be 11 x 103/mm3 and glucose was elevated to 117 mcg/dL.
During the patient’s eighth admission to a private psychi-
atric hospital, the cortisol abnormalities were so severe that
Cushing’s syndrome was considered at the beginning of the
admission. An abnormal cortisol of 14.7 mcg/dL indicated
nonsuppression and her urine free cortisol was elevated at
117 mcg/24 h. The normal range was not described in the
discharge summary but this value is definitively abnormal
according to McCann et al. [62], who report normal cortisol
as <51.1 mcg/24 h or de Bos [63] who reports <52.5 mcg/24
h. The patient was described as having a “moon face.” In
this discharge summary, her abnormal laboratory values were
noted, but no further comment was made about the presence
or absence of Cushing syndrome; this lack of comment sug-
gests to these authors that Cushing syndrome was no longer
considered at the time of discharge.
3.3.3. Data from the Later Psychiatric Admissions. At the
university hospital a WBC was found to be 17 x 103/mm3 and
abnormalities in c-reactive protein (CRP) and erythrocyte
sedimentation rate (ESR) were described (Supplementary
Table S1).
4. Retrospective Diagnosis of Catatonia Based
on DSM-5 Criteria
A DSM-5 [7] diagnosis of catatonia requires the presence of
three or more of the following symptoms: stupor, catalepsy,
waxy flexibility, mutism, negativism, posturing, mannerism,
stereotypy, agitation, grimacing, echolalia, and echopraxia.
The patient exhibited (see Supplementary Table S2) stupor,
mutism, negativism, posturing, stereotypy, and agitation.The
DSM-5 recognizes catatonia as a specifier for various psychi-
atric conditions, as a disorder due to amedical condition, and
as unspecified catatonia when an underlying or associated
disorder cannot be easily identified. Despite her episodes of
psychosis and fear, she did notmeet criteria for schizophrenia
or a major mood disorder. Furthermore, the extensive medi-
cal workup failed to reveal an underlyingmedical explanation
for her catatonia. Both authors agreed with a retrospective
diagnosis of DSM-5 unspecified catatonia.
5. Discussion
5.1. Case Summary. At the time of discharge, the senior
author believed that the patient had an idiopathic familial
type of catatonia. Her catatonia appeared to be exacerbated
by her menses. The patient’s menses stopped and she became
menopausal during her observation period.The elevations in
CK and LDH, leukocytosis, thrombocytosis, and hypercorti-
solemia appeared to reflect the duration and severity of her
catatonic episodes.
5.2. CK and LDH Elevations
5.2.1. Relationship of CK to LDH. At the state psychiatric hos-
pital, CK appeared to be definitivelymore sensitive than LDH
for monitoring the catatonic exacerbations of our patient.
LDH was only elevated in the very long second catatonic
episode and only occurred when CK had reached >1000
U/L. Our observations can be compared to a study [64] of
professional racing cyclists, in which CK elevations occurred
after a 6-day race of 800 kmwhile LDHelevations required 20
days of racing over 2700 km. This study on cyclists suggests
that LDH elevation requires the accumulation of weeks of
muscle destruction. When compared with CK elevations,
LDH elevations appeared to reflect greater severity and
chronicity during the catatonic episode.
There were no CK values available from the 17 psychiatric
admissions prior to the state psychiatric hospital admission.
CK elevations cannot be ruled out since LDH elevations
were documented at least twice. CK was elevated during
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admissions 19 and 20 and the patient was initially considered
to have NMS.
5.2.2. Relationship of LDH to Biological Variables Other
Than CK. Our linear regression analysis with LDH as the
dependent variable suggested that cortisol elevations were
significantly associated with LDH elevations, although we
were unable to find any specific literature that has demon-
strated this association. Still, the exercise physiology literature
[65, 66] describes LDH and cortisol values as markers of
physiologic reactions to physical stress although they do not
discuss whether they are in any way related.
5.2.3. CK as a Possible Biological Marker for Monitoring
Catatonia Severity. There is general agreement that CK can
be used as a marker for NMS [67] and some authors propose
that it can be used to monitor NMS [68]. It seems reasonable
to us that CK can be used similarly in catatonia. As a matter
of fact, in 1996, Northoff et al. first described elevated CK
in 32 acutely catatonic patients [50]. Since the senior author
treated our patient in the late 1990s, he has used CK values
as an objective sign for monitoring catatonia patients [51,
52], particularly when no clinician was available to complete
repeated assessments with catatonia scales for longitudinally
monitoring the patient.
5.3. Fear and Catatonia. On the first day (day 194) that the
senior author saw the patient experiencing the first signs of
catatonia, hemisdiagnosed herwith overwhelming anxiety of
unknown cause and treated her with oral lorazepam. This is
not surprising since there is consistent literature on the asso-
ciation between catatonia and fear, reviewed by Moskowitz
[69]. In his paper “Scared Stiff”, Moskowitz conceptualizes
catatonia from an evolutionary point of view as a regression
to response to predators in which the stuporous phase reflects
the release of tonic immobility while the excitement phase
reflects the fight-flight strategy. As a matter of fact, in the first
description of catatonia, Kahlbaum [2] described catatonic
patients as appearing as if theywere “being frozen after a great
fright.” One century later, Gallup and Maser [70] concluded
that catatonia was a behavioral response based on “primitive
defenses against predators that nowmisfire under conditions
of exaggerated stress.”Then, Perkins [71] explained, “It seems
possible therefore to view catatonia as the ultimate response
to fear in a person who is under enormous psychological and
physical stress and in whom regression to a primitive form
of expression has occurred. The presence of organic brain
diseasemay be necessary to lower the threshold for the release
of this form of behaviour.”
Rosebush andMazurek [72] suspect that catatonia can be
treated with lorazepam because since “the catatonic patient is
‘frozen with fear,’ one would expect the anxiolytic properties
of lorazepammight be central to its ability to treat catatonia.”
Recently Fink and Shorter [73] have proposed that “persistent
fear occupies the mind of catatonic patients.”
The hypothesis that catatonia is a fear response is espe-
cially applicable to our patient because there is definitive
agreement in the literature that psychological stressors induce
cortisol release, particularly when a test subject feels a
situation is uncontrollable or that they are being judged and
evaluated by others [74]. The fear associated with catatonia
could explain why our patient had hypercortisolemia during
the catatonic exacerbations.
5.4. WBC and ANC Elevations. Although there is debate,
glucocorticoid-induced elevation of ANC is thought to occur
through multiple mechanisms including enhanced mobiliza-
tion of neutrophils from the bone marrow, demargination of
neutrophils into active circulation, and prolonged intravascu-
lar neutrophil half-life [75]. A recent study has demonstrated
that glucocorticoids may alter the mechanical properties of
neutrophils such that they become more mobile and are
able to demarginate and circulate more easily [76]. Increased
neutrophil mobility promoted by hypercortisolemia was
probably an important issue in this patient since we identify
dramatic changes in WBC count within hours on the same
day. On day 1276 the first WBC checked in the emergency
department was 24.2 x 103/mm3 with an ANC of 19.7 x
103/mm3. A few hours later at the state psychiatric hospital
the WBC had decreased to 16.2 x 103/mm3 with an ANC of
12.0 x 103/mm3.
As (1) the literature definitively supports the concept
that hypercortisolemia can increase WBC and (2) in this
patient, during periods of high cortisol, mean and abnormal
WBCs appeared higher (middle panel in Supplementary
Table S3), it is clear that the WBC elevations were a sign
of hypercortisolemia during the catatonic exacerbations. As
there is evidence for extreme variations of WBC within a
few hours (for example, day 1276), we suspect that increased
neutrophil demargination was a major contributor to WBC
peaks >20 x 103/mm3.
5.5. Platelets. The standard laboratory upper limit for platelet
count is 444,000/mm3, a value that this patient almost always
exceeded. As the patient refused further studies, including a
bone marrow biopsy, it cannot be ruled out that the throm-
bocytosis may have other causes independent of catatonia or
that catatonia only exacerbated the underlying mechanism
causing the thrombocytosis. The limited data that were
available from the prior and later admissions indicated values
usually within normal laboratory range or mild elevations.
The relationship of platelet count in this patient with
catatonic exacerbations and hypercortisolemia remains
somewhat uncertain. We were unable to find any literature
supporting platelet elevations during hypercortisolemia and
failed to find any significant correlations between platelet
count and any other lab values. However, this patient’s
platelets tended to trend up with other biological abnormal-
ities during the worst exacerbations and, more importantly,
the extremely high values >800,000/mm3 only occurred dur-
ing the very prolonged and severe second catatonic episode.
Therefore, we suspect that platelet elevation was yet onemore
of the biological abnormalities associated with catatonia
in this patient, although we are not sure of the mediating
mechanism. It appears that the greatest peaks in platelet
counts arose a few weeks after the highest WBC peaks.
Platelet counts tookmore than 150 days to normalize between
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the second and the third catatonic episodes. So, it appears that
the biological process which underlies the platelet elevations
in this patient may take longer to have full effect and
resolve.
5.6. Serum Iron Levels. The iron treatment corrected the
mild iron lab abnormalities within six months but did not
appear to be associated with changes in catatonic symptoms;
moreover, the patient recovered only after receiving ECT.
The literature reviewed in the Introduction indicates that in
catatonic patients serum iron values are frequently relatively
low but within normal range; their contribution to the
catatonic episodes is unclear. Similarly, in our patient, it is not
clear that her mild iron deficiency played any important role
in exacerbation and/or recovery.
5.7. Menses. We suggest a two-hit hypothesis of the menses
and catatonia: the patient suffered from episodes of catatonia
when (1) she had onset of her menses and (2) she suffered
froma lapse in treatmentwith either benzodiazepines or ECT.
As detailed in Section 3.1, it is known that at times she had
her menses but was not catatonic; at other times she abruptly
stopped her benzodiazepines and suffered seizures but not
catatonia. It therefore seems that both the lack of effective
treatment and the onset of the menses were required for the
patient to develop an episode of catatonia.
Kraepelin [4], Brockington [38], Kobayashi and Kato
[41], Cookson [32], and Leonhard [24] described catatonic
patients whose catatonia (or periodic psychoses) was influ-
enced by the menstrual cycle. Our case represents the only
example of periodic catatonia specifically exacerbated by
the menses. During the second catatonic episode, there was
significant CK elevation (p=0.002) during the menses, with
a median CK of 477 U/L on the 7 days with menses and a
median CK of 71 U/L on the 39 days without menses. No
similar menstrual exacerbations could be demonstrated with
other biological abnormalities, but data was limited and only
available for the second catatonic episode.
5.8. Role of Heredity. We suspect that heredity contributed
to the patient’s catatonic episodes. Her paternal grandmother
probably died of severe agitation during an episode of excited
catatonia. Her death occurred in her 30s, which is the
same age that the patient started having catatonic episodes.
The father would not be expected to demonstrate catatonia
exacerbated by the menses, and the siblings were only half-
siblings. The patient did not have any children. Leonhard
[24] and his followers inGermany [25–27] described periodic
catatonia as a familial disorder; our patient probably had a
form of familial periodic catatonia.
5.9. Limitations. This study is limited due to the uniqueness
of this case and the lack of comparison; as a matter of fact,
a thorough literature review failed to reveal any other case
reports or case series with comparable (1) long-term follow-
up and data collection, (2) presentation of catatonia exacer-
bated by the menses, (3) LDH elevations in catatonia, and
(4) unexplained platelet elevations in catatonia. Therefore,
while this case demonstrates some unprecedented findings,
we have over 1,000 days of close follow-up and over 1,500 days
of inpatient monitoring. Similarly, the laboratory and clinical
data available from other psychiatric hospitals are certainly
limited, but we have gathered information over 25 years and
20 hospitalizations.
In the late 1990s, catatonic patients were not studied
for risk of pulmonary embolism using fibrin D-dimer [77].
Currently, if we had to treat and manage a patient who was
catatonic for 17 months and who had platelet elevations,
we would measure fibrin D-dimers to establish the risk for
pulmonary embolism, which can be lethal [78, 79].
5.10. Suggestions for Further Studies. We have presented
years of clinical observations and drawn from hundreds of
biological measurements in a patient with familial periodic
catatonia. This case may have implications for those patients
with (1) familial periodic catatonia, (2) fear as a salient feature
of catatonia, and (3) any type of catatonia.
Although familial periodic catatonia is probably rare,
catatonia in general is underdiagnosed and undertreated
[79], so it is unknown how many cases of familial periodic
catatonia go unnoticed by clinicians. Leonhard [24] and
others [25–27] describe families with periodic catatonia but
do not comment on the presence of biological abnormalities.
There is great need to study biological abnormalities in
patients with familial catatonia.
If fear is present in at least a significant number of patients
with catatonia, hypercortisolemia may be more common
than is recognized in patients with catatonia. Table 1 describes
the limited number of published catatonic patients examined
for hypercortisolemia. If it is correct that fear is crucial
in catatonia, it would not be surprising if many catatonic
patients had hypercortisolemia, though this has never been
systematically studied. As with our patient, some of these
catatonic patientswith intense fearmayhave leukocytosis and
neutrophilia in the absence of infections. As discussed earlier,
leukocytosis was described in catatonic patients by Gjessing
[9, 10] and more recently by Lee et al. [28, 29].
As Section 5.2.3 describes, we propose that clinicians
treating any kind of catatonic patient may consider using
CK as an objective marker of severity in catatonia and that
researchers should complete studies to explore this issue.
6. Conclusion
After a review of the literature from the early 20th cen-
tury forward, we find that (1) menstrual exacerbations of
catatonia, (2) biological abnormalities of periodic catatonia,
and (3) familial periodic catatonia support the uniqueness
of this case. Its originality is demonstrated by the long-term
follow-up, including 4 years of prospective data including
4 catatonic episodes (the second one lasting 17 months)
and an exhaustive study of biological abnormalities. Besides
the 4-year admission at the state hospital, we gathered data
from 14 years of previous admissions and from the 7 years
following; these limited laboratory data also suggested that
other catatonic episodes had similar biological abnormalities.
Exacerbations of catatonia with the menstrual cycle have
been described before but no previous description had
10 Case Reports in Psychiatry
similar detail.Moreover, during the second catatonic episode,
we observed a significant CK elevation during the menses.
Prior descriptions of catatonic patients included leukocytosis
by Gjessing [9, 10] and Lee et al. [28, 29] and some cases
of cortisol elevation by other authors [31, 33, 34], but our
case is unique due to its long-term follow-up and suggests
an association between hypercortisolemia and leukocytosis
with neutrophilia. We have previously used CK to follow
catatonic patients [51, 52], but this is the first case in which
LDH not only appears to be a marker, of the severity and per-
sistence of the muscle destruction, but also reflects the other
biological processes present in the catatonic episodes of this
patient.
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